The Scottish Mail on Sunday

Drug firms hike cost of life-saving pills by 800% ...

- and blame Covid-19 By Sally Wardle

DRUG firms could be investigat­ed by the Government’s watchdog for ‘price gouging’ – inflating the cost of vital medication needed by millions of Britons – amid concerns they may profit from the Covid-19 pandemic. Prices paid by NHS chemists for antidepres­sants and a breast cancer treatment have soared by more than 800 per cent in recent weeks, The Mail on Sunday can reveal.

And dozens of other commonly taken drugs have seen extraordin­ary price increases during the pandemic. These include painkiller­s such as ibuprofen and co-codamol, antibiotic­s, and even medication to treat overactive bladders.

While some pharmacies have paid over the odds in order to meet patient needs, others have been unable to – meaning that thousands of Britons may have faced delays or struggled to get the treatment they need.

Some chemists say that due to shortages, they have at times not been able to give heart patients aspirin, which is prescribed as a blood thinner to prevent heart attacks.

Companies that supply the drugs claim price hikes are due to increased demand, lockdowns causing hold-ups in production and problems getting products from India and China, where most medicines are made.

But Government officials are also concerned that ‘a minority of bad apples’ may artificial­ly inflate prices during the pandemic to make money.

Other examples of price gouging, investigat­ed by consumer watchdogs in recent months, include high-demand products such as hand sanitiser, bleach and baby formula.

EXPERTS are also warning that if a second wave of coronaviru­s hits in the winter, when demand for medicines is typically higher, there could be further cost increases and shortages. ‘When there are shortages, a pharmacist will do whatever they can to source that product,’ says Leyla Hannbeck, chief executive of the Associatio­n of Independen­t Multiple Pharmacies.

‘If they can’t get hold of it, patients will sometimes be switched on to similar-acting medicines. But with some antidepres­sants, for example, it’s not very easy to just switch a patient from one medicine to another – and if someone suffers from anxiety and depression, not having their medicine will make them more anxious.

‘Shortages of cancer drugs are also particular­ly difficult.

‘In a lot of instances, patients are put on drugs for specific reasons and it’s difficult to just substitute them for something else.’

The process of making and distributi­ng prescripti­on drugs is complex. Firstly, the raw ingredient­s that make them work, known as active pharmaceut­ical ingredient­s, need to be manufactur­ed. These are then transporte­d to factories where they are made into tablets or prepared for injections into the patient.

The finished products are traded between wholesaler­s until they are sold to pharmacies and hospitals, which dispense them to patients.

Today, the majority of generics – cheap, unbranded versions of commonly taken drugs – are from abroad. Just 20 to 25 per cent of those supplied to the NHS for use in pharmacies and hospitals are made in the UK.

About a quarter come from India, and India gets 70 per cent of its raw ingredient­s from China.

‘We are at the end of a very long supply chain for some drugs,’ says Dr Andrew Hill, honorary senior visiting research fellow in the Institute of Translatio­nal Medicine at the University of Liverpool.

‘If anything breaks down, then we are in trouble.’

In February, some factories in China ceased production as Covid19 spread. And in March, India introduced restrictio­ns on the drugs it would export, so it could meet its own demand for medicines. The effects of the disruption caused to the supply chain are still being felt in the UK.

Fin McCaul, who has owned and run a pharmacy in north Manchester for nearly 40 years, says two wholesaler­s he uses regularly have been recently out of stock of aspirin.‘We have been spending a lot of time trying to source appropriat­e products, and working with GPs to find alternativ­es that patients can switch to,’ he says.

Shortages of prescripti­on drugs can also be costly.

‘Medicines are subject to supply and demand,’ explains Martin Sawer, executive director at the Healthcare Distributi­on Associatio­n, which represents wholesaler­s. ‘If there is plentiful supply, then the price comes down. If supply can’t meet demand straight away, then the prices go up. These prices change on a daily basis.’

The NHS reimburses pharmacist­s for prescripti­on drugs they dispense, paying a set price known as a drug tariff. But when there are problems and a drug is in short supply, pharmacies may end up paying above the listed price to get hold of it. If this happens, the Department of Health will meet the higher price and pay back pharmaimpo­rted cies – this is called a concession. The list of concession prices, published by the Pharmaceut­ical Services Negotiatin­g Committee, gives a good indication of drugs which are in short supply. A total of 43 items were listed in March, but this grew to 74 in April and 80 in May.

FIGURES from May suggest the price of antidepres­sant sertraline was up by 823 per cent, with the NHS reimbursin­g £14.32 for a pack of 100mg tablets, instead of its usual £1.55. Exemestane, a hormone therapy used to treat breast cancer in post-menopausal women, soared in price by 827 per cent. A 30-pack usually costs the NHS £6.64, but in May the concession price was £61.57.

The Government’s Competitio­n and Markets Authority has said it will investigat­e price rises throughout the supply chain during the Covid-19 pandemic and take action against any increases which it considers to be ‘unjustifia­ble’.

Warwick Smith, director-general of the British Generic Manufactur­ers Associatio­n, says: ‘If manufactur­ers increase prices for no good reason, then we will be the first to criticise them.’

As the UK prepares for a possible second wave of Covid-19, some experts argue that the supply chain must be strengthen­ed to ensure patients have access to essential, life-saving drugs.

Shortages so far have not just been limited to pharmacies, Dr Hill warns. ‘I’ve spoken to doctors who ran out of certain drugs in intensive care,’ he says.

He believes the Government must now consider how it will source drugs and the ingredient­s to make them to avoid similar problems for pharmacies and hospitals in the future. ‘At the moment, if China goes down, we don’t have another option,’ he says. ‘The key is to have at least a Plan B, if not a Plan C. As a last resort, we should have the ability to make drugs within the UK.’

For patients worried about shortages, the advice is clear. ‘Order your medicine seven days before you run out,’ pharmacist Fin McCaul says. ‘If there is an issue, this gives us time to source the medication, or speak to your GP about finding an alternativ­e.’

A Department of Health and Social Care spokesman said: ‘Fluctuatio­ns in price for generic medicines are normal, but companies must not capitalise on the pandemic by charging unjustifia­bly high prices. The Competitio­n and Markets Authority has set up a taskforce to investigat­e reports about businesses behaving unfairly, and can take action if necessary.’

 ??  ??
 ??  ??

Newspapers in English

Newspapers from United Kingdom